Debt Financing

Rockwell Medical borrows $125 million from Vantive to buy its dialysis business

RMTI

Vantive is financing its own sale with $100 million of secured term loans and a $25 million convertible note. Rockwell, which had $24.8 million of cash and investments in June, takes on rising interest margins and a dilution vote.

Investor Chat

Scorecard

RMTIDebt
Deal Terms: 5/10, Fair termsHow favorable this deal is for the company and existing shareholders, compared with similar financings. · Terms are estimated from available structured facts. Unobserved components use the median prior; transaction linkage is incomplete. · As of 2026-11-05
Fair terms
Investor Impact: 8.2/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-05
Very highHigh evidence
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-05
Mixed record
Investment Attractiveness: 6/10, Above peersThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-05
Above peers

Debt: loan financing

By the aibio.space news desk

Glass office towers rising overhead
Glass office towers rising overhead. Photo: Guillaume Bolduc guibolduc, CC0, via Wikimedia Commons. The picture shows the field, not the companies named.

Rockwell Medical (Nasdaq: RMTI) agreed on November 2 to buy the in-center hemodialysis business of Vantive Limited for a base price of $125 million, and the seller is lending it all of the money. President and Chief Executive Officer Mark Strobeck, Ph.D., called the deal "a transformative step" in the company's evolution. Its shareholders would carry $100 million of secured seller term loans with margins that rise every year, a $25 million convertible note, up to $45 million of earnout payments, and a wait until mid-2027 for closing. In Rockwell's favor, it can repay the loans at par at any time, and the loan agreement has no financial maintenance covenants. Rockwell release · November 3 filing

What Rockwell is buying

Rockwell would take all the equity of Gambro Dasco S.p.A., which runs the manufacturing campus in Medolla, Italy, and of Vantive Korea Incorporated and the business's assets elsewhere, across 35 jurisdictions. The products are concentrates, hemodialysis machines including the AK-98, water treatment systems, bloodlines and technical services, with an installed base the presentation puts at ~100,000 machines. Rockwell estimates the combined company could bring in annual revenue between $400 million and $450 million, assuming successful integration. Its own net sales were $35.1 million in the first six months of 2026. The filing warns that the acquired business is several times the size of Rockwell's existing business and operates principally outside the United States. November 3 filing · Investor presentation · August 13 quarterly filing

How the seller financing works

Vantive Finance I Limited is the lender on two $50 million term loans, guaranteed by Rockwell Transportation, Inc. and secured by substantially all of the company's assets. Both pay Term SOFR, with a 2.50% floor, plus a margin that climbs 0.75% on each anniversary of closing: Tranche A runs from 5.50% to 9.25% and Tranche B from 7.00% to 10.75%. Tranche A interest may be paid in kind at an extra 0.50%; Tranche B is cash pay. Both mature on the sixth anniversary of closing. Proceeds of new share sales, other than permitted issuances, go first to prepaying Tranche B, and a Nasdaq delisting is an event of default. The filing names no administrative agent or arranger; Vantive Finance I Limited is the only lender. November 3 filing

The $25 million convertible note goes to Vantive Manufacturing Limited in a Section 4(a)(2) private placement reported under Item 3.02. It is unsecured, subordinated to the term loans, accrues 3.0% interest in kind and converts at $14.94 a share, which the filing says is 200% of a reference price of $7.47 fixed in the note; the release calls it a 100% premium to the 15-day volume-weighted average price. Without stockholder approval under Nasdaq Listing Rule 5635, conversions stop at 19.99% of the shares outstanding before signing. By our arithmetic, the full principal would convert into more than 40% of the 4,030,465 shares outstanding on August 10, about twice the cap. Rockwell has agreed to put the question to every annual meeting after closing until it passes. The earnout pays Vantive 30% of pro forma EBITDA above $10 million a year, up to $25 million, plus $10 million each if revenue tops $480 million and $500 million. November 3 filing · August 13 quarterly filing

Rockwell's own balance sheet

The quarterly report signed by Strobeck and Senior Vice President and Chief Financial Officer Jesse Neri shows about $24.8 million of cash, cash equivalents and investments at June 30, 2026. Operations generated $1.9 million of cash in the first half, though the company still lost $0.74 per share. Its term loans with Innovatus Life Sciences Lending Fund I, L.P., continued at $8.0 million in 2024 and due January 1, 2029, will be repaid at closing. A one-for-ten reverse split on July 1 cured a Nasdaq bid price notice, and compliance was confirmed on July 16. August 13 quarterly filing · November 3 filing

DaVita, holder of the Series X Convertible Preferred Stock, can limit new debt to narrow categories, such as a working capital line of up to $5.0 million, unless it consents. The filing lists that consent as a risk and says it is not a condition to closing. Rockwell has also withdrawn its 2026 guidance and says its registered offerings are limited while the deal is pending. For most breaches of Vantive's representations, its only recourse is an insurance policy it has not yet bound. November 3 filing · Rockwell release · August 13 quarterly filing

Advisers and the road to closing

Aquilo Partners, L.P. is exclusive financial advisor to Rockwell and Gibson Dunn & Crutcher LLP is its legal counsel. Perella Weinberg Partners LP and Barclays advise Vantive, with Kirkland & Ellis LLP as counsel. Closing requires merger control and foreign investment clearances, including Italy's golden power review, Vantive's internal reorganization and separation from Baxter's information technology systems, and audited 2025 and 2026 statements of the business. Afterward, Rockwell will depend on Vantive for transition services for up to 18 months and for products from Vantive plants in Italy, Mexico, Tunisia, Germany and France. Either side may terminate if the deal has not closed by November 1, 2027, extendable to April 29, 2028, and neither pays a termination fee. November 3 filing · Rockwell release

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.